Product Description
Betrixaban is used to prevent venous thromboembolism (VTE) in hospitalized patients at risk for blood clots because of the loss or decreased ability to move around or due to other factors. Betrixaban is a factor Xa inhibitor, an anticoagulant. It works by decreasing the clotting ability of the blood and helps prevent harmful clots from forming in the blood vessels. (Sourced from: https://www.mayoclinic.org/drugs-supplements/betrixaban-oral-route/description/drg-20406393)
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | European Medicines Agency
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Venous Thromboembolism
Phase 2: Atrial Fibrillation|Atrial Flutter|Thromboembolism|Stroke|Healthy Volunteers|Injuries/wounds Unspecified
Phase 1: Healthy Volunteers|Tic Disorders|Venous Thrombosis|Neuromyelitis Optica|Venous Thromboembolism|Embolism and Thrombosis|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Protocol 16-021 â Pediatric PK | P1 |
Terminated |
Venous Thromboembolism|Neuromyelitis Optica|Venous Thrombosis|Tic Disorders|Embolism and Thrombosis |
2020-08-05 |
50% |
2022-03-13 |
Treatments |
| NCT03346083 | P1 |
Terminated |
Venous Thromboembolism |
2019-10-08 |
50% |
2024-01-14 |
Primary Endpoints|Start Date|Treatments|Trial Status |
| NCT03397888 | P1 |
Completed |
Healthy Volunteers |
2018-01-16 |
19% |
2019-03-22 |
Treatments |
| NCT02596100 | P1 |
Completed |
Healthy Volunteers |
2015-11-01 |
2019-03-20 |
Treatments |
|
| NCT00999336 | P1 |
Completed |
Kidney Diseases |
2010-02-28 |
2023-08-23 |
Primary Endpoints |
|
| NCT01765855 | P1 |
Completed |
Healthy Volunteers |
2007-10-01 |
2019-03-19 |
Treatments |
|
| NCT01765868 | P1 |
Completed |
Healthy Volunteers |
2007-10-01 |
2019-03-19 |
Treatments |
|
| NCT03330457 | P2 |
Terminated |
Injuries/wounds Unspecified|Healthy Volunteers |
2016-02-22 |
32% |
2020-04-14 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date |
| NCT01229254 | P2 |
Completed |
Atrial Fibrillation|Atrial Flutter |
2010-12-01 |
2019-03-19 |
Treatments |
|
| EXPLORE Xa | P2 |
Completed |
Stroke|Atrial Fibrillation |
2010-04-30 |
2022-03-12 |
Treatments |
|
| EXPLORE-Xa | P2 |
Completed |
Atrial Fibrillation |
2009-08-01 |
2019-03-18 |
Treatments |
|
| EXPERT | P2 |
Completed |
Thromboembolism |
2007-01-01 |
2019-03-22 |
Treatments |
|
| 2012-000255-13 | P3 |
Completed |
Venous Thromboembolism |
2016-01-31 |
2025-05-06 |
Treatments |
|
| APEX | P3 |
Completed |
Venous Thromboembolism |
2015-12-01 |
2019-03-19 |
Treatments |